Dr Jorge Cortes speaks to ecancer about the primary analysis from the OPTIC trial, a dose-ranging study of 3 starting doses of ponatinib.

Initially, he mentions the background of the trial. Dr Cortes then discusses the methodology and results of this trial. He says; results from this OPTIC primary analysis show a trend toward dose-dependent efficacy and safety and may provide a refined understanding of the ponatinib benefit: Risk profile and its relation to dose. Mature data from continued follow-up may support an alternate dosing regimen for patients with chronic-phase chronic myeloid leukaemia (CP-CML).

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.